Merck Investors Rip Fee Requests In $688M Vytorin Deal

Law360, New York (August 6, 2013, 3:08 PM EDT) -- Investors in two class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results for their anti-cholesterol drug Vytorin challenged a proposed $688 million settlement of the cases on Monday, saying attorneys' fee requests in the actions were too high.

Class counsel in the Schering-Plough action have asked for $80 million, while counsel in the Merck class action have asked for $60 million. The objectors urged the New Jersey federal court to trim the amounts based on the actual time and effort that counsel...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.